HCG (Human Chorionic Gonadotropin)Hormone TherapySafety Rating 8/10

Primary research areaTRT adjunct (testicular atrophy

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeTRT: 250–500 IU SC 2–3x/week. PCT: 1000–2000 IU SC daily for 10 days. Female fertility: 5000–10000 IU trigger shot.
AdministrationVaries
Safety8/10 · FDA-approved
NCAA D1Banned

Price Comparison

Compare vendors

5 vendors competing

VendorPrice$ / IUUpdated
Swiss ChemsBest $/IUCOA ✓ · 3P$28.99$0.0058Apr 17, 2026Buy →
$25 off $100+·auto
Olympex SolutionsCOA ✓ · 3P$39.99$0.0080May 14, 2026Buy →
SomaChemsCOA ✓ · 3P$39.99$49.99−20% · code PEPTIDEPRICES$0.0080May 14, 2026Buy →
Ascension PeptidesCOA ✓ · 3P$49.99$99.99−50% · code peptidepri$0.0100Apr 16, 2026Buy →
LeoLab RxCOA ✓ · 3P$80.00$0.0160May 14, 2026Buy →

Overview

About HCG

Mechanism of action

Glycoprotein hormone; mimics LH; binds LH receptors on Leydig cells; stimulates testosterone production; maintains testicular size and fertility during TRT; stimulates ovulation in females.

Safety profile

Gynecomastia risk (aromatization of testosterone), testicular pain, headache, mood swings, water retention, desensitization of Leydig cells with high-dose continuous use. · Decades of use; OHSS risk in women; headache; very well-characterized

📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on HCG

Research

Studies & key findings

  • hCG, a glycoprotein hormone with full LH-receptor agonism, has been FDA-approved since 1939 for cryptorchidism and hypogonadotropic hypogonadism; it stimulates Leydig cell testosterone synthesis and seminiferous tubule spermatogenesis, serving as the pharmacological substitute for LH in men with secondary hypogonadal infertility.
  • A randomized double-blind study showed that adding low-dose hCG (250–500 IU every other day) to testosterone replacement therapy limits the decline in intratesticular testosterone to only 7% (vs. 94% decline with TRT alone) and prevents the azoospermia that typically develops within 10 weeks of TRT — the principal clinical use case for hCG co-administration.

5 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch